When was Transcripta Bio founded?

Transcripta Bio was founded in 2020 and raised its 1st funding round 4 years after it was founded.

Where is Transcripta Bio located?

Transcripta Bio is headquartered in Palo Alto, United States.

Who is the current CEO of Transcripta Bio?

Christopher Moxham of Transcripta Bio. They have also founded 1 company.

How many employees does Transcripta Bio have?

As of Sep 30, 2026, the latest employee count at Transcripta Bio is 18.

Is Transcripta Bio a funded company?

Transcripta Bio is a funded company, having raised a total of $34M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Apr 29, 2024.

When was the latest funding round of Transcripta Bio?

Transcripta Bio's latest funding was a $***** Series B round on Jul 22, 2026, with participation from 4 investors.

Where does Transcripta Bio rank among its competitors?

Transcripta Bio ranks 2nd amongst 26 active competitors, of which 11 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Transcripta Bio, which secured $24M in Jul, 2026.

Who are the top competitors of Transcripta Bio?

Transcripta Bio's top competitors include Formation Bio, Cellarity and Arpeggio. Among them, Transcripta Bio secured the most recent funding round in July, 2026.

Transcripta Bio - 2026 Company Profile, Team, Funding & Competitors

Transcripta Bio is a series B company based in Palo Alto (United States), founded in 2020 by Omid Karkouti and Christopher Moxham. It operates as an AI-powered platform for drug screening and development. Transcripta Bio has raised $34M in funding. The company has 26 active competitors, including 11 that are funded. Its top competitors include companies like Formation Bio, Cellarity and Arpeggio.

Company Details

AI-powered platform for drug screening and development. It involves using artificial intelligence modeling to discover and predict the effects of drugs at a transcriptome scale, screening compounds for disease-modifying ability, and synthesizing and testing candidates in the lab to identify novel therapies.

Website: www.transcriptabio.com/
Social
Email ID: *****@transcriptabio.com

Key Metrics

Founded Year

2020

Location

Palo Alto, United States

Stage

Series B

Total Funding

$34M in 2 rounds

Latest Funding Round

Series B, Jul 22, 2026, $*****

Investors

Mayo Clinic Ventures & 3 more

Ranked

2^nd among 26 active competitors

Employee Count

18 as on Sep 30, 2026

Similar Companies

Formation Bio & 32 more

View Transcripta Bio's full profile

Transcripta Bio has raised a total funding of $34M over 2 rounds. Its first funding round was on Apr 29, 2024. Its latest funding round was a Series B round on Jul 22, 2026 for $*****. 4 investors participated in its latest round. Transcripta Bio has 4 institutional investors.

Here is the list of recent funding rounds of Transcripta Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 22, 2026	2472439	Series B	8150570	8442108	5209412	2952608
Apr 29, 2024	3704811	Series A	4073592	5629506	6259379	JAZZ Venture Partners & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Transcripta Bio's funding rounds and investors

The founders of Transcripta Bio are Omid Karkouti and Christopher Moxham. Christopher Moxham is the CEO of Transcripta Bio.

Here are the details of Transcripta Bio's key team members:

Omid Karkouti: Co-Founder and COO of Transcripta Bio.
Christopher Moxham: Founder & CEO of Transcripta Bio.

View details of Transcripta Bio's Founder profiles and Board Members

Transcripta Bio's employee count trend

Transcripta Bio has 18 employees as of Sep 26. Here is Transcripta Bio's employee count trend over the years:

Employee count trend for Transcripta Bio

Uncover Transcripta Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Transcripta Bio include Formation Bio, Cellarity and Arpeggio. Here is the list of Top 10 competitors of Transcripta Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Formation Bio 2016, New York City (United States), Series D	Provider of AI-powered drug discovery platform for various diseases	$608M	Andreessen Horowitz, Sequoia Capital & 17 others	72/100
2nd	Transcripta Bio 2020, Palo Alto (United States), Series B	AI-powered platform for drug screening and development	$34M	Mayo Clinic Ventures, JAZZ Venture Partners ... & 2 others	59/100
3rd	Cellarity 2015, Cambridge (United States), Series C	AI-powered drug design and development platform	$294M	Pictet Group, The Baupost Group & 6 others	58/100
4th	Arpeggio 2017, Boulder (United States), Series B	Provider of drug discovery platform for the treatment of cancer	$49.5M	Y Combinator, FundersClub & 15 others	52/100
5th	Seragon 2005, Irvine (United States), Series A	Provider of AI-based platform for epigenetics and transcriptomics for treating aging and physiological disorders	$30M	VenBio, Aisling Capital & 3 others	39/100
6th	Portrai 2021, Seoul (South Korea), Series B	Provider of spatial transcriptomics and AI to accelerate drug discovery and biomarker identification	$9.87M	STIC Ventures, Pearl Abyss Capital & 7 others	35/100
7th	Serna Bio 2021, London (United Kingdom), Seed	Provider of AI-enabled drug discovery platform for various diseases	$500K	Hummingbird Ventures, Y Combinator	30/100
8th	Yuce Biotechnology 2015, Shenzhen (China), Series B	Developer of gene detection services for precise immunotherapy of tumors	-	IDG Capital, Puhua Capital & 2 others	27/100
9th	Rarebase 2020, Palo Alto (United States), Unfunded	Provider of AI-based drug discovery platform for rare diseases	-	-	27/100
10th	Ocean Genomics 2018, Pittsburgh (United States), Seed	Developer of a transcriptome analysis platform using AI	-	Accenture	25/100